Last reviewed · How we verify

Intravenous iron supplementation

University of Pecs · FDA-approved active Small molecule

Intravenous iron supplementation replenishes depleted iron stores by delivering iron directly into the bloodstream for absorption and utilization in hemoglobin and myoglobin synthesis.

Intravenous iron supplementation replenishes depleted iron stores by delivering iron directly into the bloodstream for absorption and utilization in hemoglobin and myoglobin synthesis. Used for Iron deficiency anemia, Anemia of chronic kidney disease, Iron deficiency in patients intolerant or unresponsive to oral iron therapy.

At a glance

Generic nameIntravenous iron supplementation
SponsorUniversity of Pecs
Drug classIron supplement
TargetIron (Fe2+/Fe3+) for hemoglobin and myoglobin synthesis
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Iron is an essential mineral required for oxygen transport via hemoglobin in red blood cells and for energy production in mitochondria. IV iron bypasses gastrointestinal absorption limitations, allowing rapid repletion of iron stores in patients with iron deficiency anemia, chronic kidney disease, or those intolerant of oral iron. The iron is incorporated into transferrin for transport and subsequently utilized by erythroid progenitor cells and other iron-dependent tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: